(点击 16 次)

New Technology of Cardiac Medical Diagnosis-Magnetocardiogram (MCG)

Recently, the British medical technology company Creavo Medical Technologies announced that it has further expanded its financing of 17.5 million US dollars. The investor is jointly led by IP Group plc and Coutts Private Bank. Other investors include the original shareholder University of Leeds (University of Leeds, UK), as well as from Europe. And China’s new private equity firm Parkwalk Advisors and Puhua Capital Ltd. The investment received will continue to be used to support Creavo’s business strategy, team building, and to promote its proprietary new medical diagnostic technology-Magnetocardiogram (MCG).

Founded in 2014, Creavo is focused on the commercial development of advanced sensing technologies for biomagnetic images of human organs, which are used to detect and Display magnetic images of organs to help diagnose diseases. This organ magnetic map sensing technology is the result of 10 years of concentrated research by the team of Professor Varcoe from the University of Leeds in the United Kingdom. Its core patented product is an emergency-deployable magnetocardiogram device, which can measure, display and store electromagnetic fluctuations caused by heart activity by detecting magnetic cardiogram (MCG).

(Image source: Creavo’s official YouTube)

This technology can meet the clinical emergency needs of heart disease worldwide, and can help doctors quickly screen patients for signs of a serious heart attack when they are admitted to the hospital. Early recognition and diagnosis of heart attack can reduce patient anxiety, win the best time for rescue, reduce bedridden hospitalization, and save medical resources. The equipment will ease the expenditure of the British healthcare system and is expected to save 200 million pounds a year.

In addition to emergency screening and diagnosis applications in the emergency department, the device has a series of other potential applications. For example, it can be used to analyze and predict sudden cardiac death arrhythmia, and it can also be used for the diagnosis of other organ diseases.

“The participation of famous investors such as Parkwalk Advisors and PricewaterhouseCoopers represents a high degree of recognition of our company’s business strategy, team and technology.” said Mr. Robert Barr, Chairman of Creavo. He said that Creavo will continue to promote the commercialization of patented technology, and the short-term goal is to apply for listing in Europe. They will promote the development of relevant clinical research in the UK, and plan to open up the US market operation and relevant clinical research.


Recently, the British medical technology company Creavo Medical Techno…